시장보고서
상품코드
1623515

혈액 배양 검사 시장 : 방법별, 제품별, 기술별, 용도별, 최종 사용자별, 지역별, 범위 및 예측

Blood Culture Tests Market By Method, By Product, By Technology, By Application, By End-User, By Geography Scope And Forecast

발행일: | 리서치사: Verified Market Research | 페이지 정보: 영문 202 Pages | 배송안내 : 2-3일 (영업일 기준)

    
    
    



※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

혈액 배양 검사 시장 규모와 예측

혈액 배양 검사 시장은 2024년에 약 53억 9,000만 달러로 평가되었고, 2024년부터 2031년에 걸쳐 약 8.81%의 연평균 복합 성장률(CAGR)로 성장하고, 2031년에는 99억 7,000만 달러에 달할 것으로 예측되고 있습니다. 혈액 배양 검사는 혈류 중 박테리아, 곰팡이 및 기타 미생물의 존재를 감지합니다. 혈액 배양 검사는 환자에게 발열, 오한, 빠른 심박수 또는 혼란 등의 심각한 감염 증상이 나타날 때 사용됩니다. 혈액 배양 검사는 혈류로 확산될 가능성이 있는 감염을 진단하는 데 매우 중요합니다.

혈액 배양 검사는 심각한 감염을 관리하고 치료 정책을 결정하는 데 필수적입니다.

세계 건강 관리 지출 증가와 의료 종사자와 환자의 감염에 대한 지식 향상이 결합되어 혈액 배양 검사에 대한 수요가 증가하고 있습니다.

세계 혈액 배양 검사 시장 역학

세계 혈액 배양 검사 시장을 형성하는 주요 시장 역학

주요 촉진요인

혈류 감염의 높은 발생률 :

혈류 감염은 전 세계적으로 이환율과 사망률의 주요 원인이 되고 있습니다. 미국에서는 매년 60만 건 이상의 혈류 감염 사례가 발생하는 것으로 추정되며, 이는 상당한 건강 관리 비용이 듭니다.

신속 진단 기술에 대한 수요 증가 :

적절한 항생제 치료를 위해 혈류 감염을 보다 빠르고 정확하게 진단할 필요성이 높아지고 있습니다.

감염의 높은 유병률 :

세계적으로 패혈증, 폐렴, 수막염 등의 부담은 증가하고 있습니다.

노년 인구 증가 :

노인들은 면역력이 떨어지기 때문에 감염의 위험성이 더 높습니다.

주요 과제

해석의 복잡성 :

오염물질과 임상적으로 중요한 병원체를 구별할 필요가 있기 때문에 혈액 배양 결과의 해석은 어렵습니다. 설문 조사에 따르면 검사실의 상당한 비율(79%)이 정확한 해석을 위해서는 병원체의 식별이 중요하다고 생각합니다.

시간이 많이 걸리는 과정 :

종래의 혈액 배양 검사에서는 결과가 나오기까지 며칠 걸리는 경우가 많아, 진단이나 치료가 지연됩니다. 결과에 부정적인 영향을 미칠 수 있습니다.

자동화 시스템의 높은 비용 :

자동 혈액 배양 시스템의 초기 투자는 50,000달러에서 100,000달러로 고액이기 때문에 소규모 의료 시설에서는 이러한 기술을 채택하기가 어렵습니다.

오염 위험 :

혈액 배양 오염은 여전히 심각한 문제이며 진단 및 치료 결정을 복잡하게 하는 위양성 결과로 이어집니다.

주요 동향 :

기술 진보 :

자동 혈액 배양 시스템의 혁신은 검사의 효율성과 정확성을 향상시켜 줍니다.

감염증 발생률 증가 :

의료 관련 감염은 증가하고 있으며 미국에서는 입원 환자의 약 31명 중 1명이 감염증을 앓고 있습니다.

건강 관리 지출 증가 :

세계 건강 관리 지출 증가는 혈액 배양 검사를 포함한 고급 진단 솔루션의 채택을 촉진합니다.

패혈증 진단에 주목 :

미국에서는 연간 약 170만 명이 앓고 있는 패혈증을 진단하는 데 혈액 배양 검사의 중요성이 인식되고 있어 시장 수요를 더욱 밀어 올리고 있습니다.

목차

제1장 세계의 혈액 배양 검사 시장 서문

  • 시장 개요
  • 조사 범위
  • 전제조건

제2장 주요 요약

제3장 VERIFIED MARKET RESEARCH의 조사 방법

  • 데이터 마이닝
  • 밸리데이션
  • 1차 자료
  • 데이터 소스 일람

제4장 세계의 혈액 배양 검사 시장 전망

  • 개요
  • 시장 역학
    • 성장 촉진요인
    • 성장 억제요인
    • 기회
  • Porter's Five Forces 모델
  • 밸류체인 분석

제5장 세계의 혈액 배양 검사 시장 : 제품별

  • 개요
  • 기구
  • 혈액 배양 배지
  • 분석 키트 및 시약
  • 혈액 배양 액세서리

제6장 세계의 혈액 배양 검사 시장 : 기술별

  • 개요
  • 중합효소 연쇄반응(PCR)
  • 마이크로어레이
  • 배양 기반 기술
  • 단백질체학 기술

제7장 세계의 혈액 배양 검사 시장 : 용도별

  • 개요
  • 균혈증
  • 진균증
  • 마이코박테리아 검출

제8장 세계의 혈액 배양 검사 시장 : 지역별

  • 개요
  • 북미
    • 미국
    • 캐나다
    • 멕시코
  • 유럽
    • 독일
    • 영국
    • 프랑스
    • 기타 유럽
  • 아시아태평양
    • 중국
    • 일본
    • 인도
    • 기타 아시아태평양
  • 세계 기타 지역
    • 라틴아메리카
    • 중동 및 아프리카

제9장 세계의 혈액 배양 검사 시장 경쟁 구도

  • 개요
  • 각사 시장 랭킹
  • 주요 발전 전략

제10장 기업 프로파일

  • Biomerieux SA
  • Nanosphere, Inc.
  • Becton, Dickinson and Company
  • Roche Diagnostics
  • Thermo Fisher Scientific, Inc.
  • Bruker Corporation
  • Cepheid(Danaher Corporation)

제11장 부록

  • 관련 조사
KTH 25.01.23

Blood Culture Tests Market Size And Forecast

The Blood Culture Tests Market was valued at approximately USD 5.39 Billion in 2024 and is anticipated to reach USD 9.97 Billion by 2031, growing at a CAGR of about 8.81% from 2024 to 2031. A blood culture test is a diagnostic procedure used to detect the presence of bacteria, fungi, or other microorganisms in the bloodstream, which can indicate a systemic infection such as bacteremia or sepsis. Blood cultures are ordered when patients exhibit symptoms of severe infection, such as fever, chills, rapid heart rate, or confusion. They are crucial for diagnosing infections that may have spread to the bloodstream.

Blood culture tests are vital for managing serious infections and guiding treatment decisions. They help prevent complications such as sepsis, which can be life-threatening if not addressed promptly.

Growing worldwide healthcare expenditure, combined with improved knowledge of infectious diseases among healthcare providers and patients, has increased demand for blood culture testing.

Global Blood Culture Tests Market Dynamics

The key market dynamics that are shaping the global blood culture tests market include:

Key Drivers

High Incidence of Bloodstream Infections:

Bloodstream infections are a major cause of morbidity and mortality worldwide. In the United States, it is estimated that there are over 600,000 cases of bloodstream infections annually, resulting in significant healthcare costs.

Growing Demand for Rapid Diagnostic Techniques:

There is an increasing need for faster and more accurate diagnosis of bloodstream infections to guide appropriate antibiotic therapy. This has driven the development and adoption of advanced blood culture technologies.

High Prevalence of Infectious Diseases:

The global burden of infectious diseases, such as sepsis, pneumonia, and meningitis, has been rising. For example, in 2017, sepsis was estimated to affect 48.9 million people and result in 11 million deaths worldwide.

Rising Geriatric Population:

The elderly population is more susceptible to infections due to weakened immune systems. The global population aged 65 and above is projected to increase from 727 million in 2020 to 1.5 billion in 2050.

Key Challenges:

Complexity in Interpretation:

Interpreting blood culture results can be challenging due to the need to distinguish between contaminants and clinically significant pathogens. This complexity increases reliance on skilled professionals, which can hinder market growth. Studies indicate that a significant percentage of laboratories (79%) find organism identity crucial for accurate interpretation .

Time-Consuming Process:

Traditional blood culture tests often take several days to yield results, delaying diagnosis and treatment. This prolonged wait can negatively impact patient outcomes, as the average turnaround time in the U.S. is typically 2-3 days .

High Costs of Automated Systems:

The initial investment for automated blood culture systems can be substantial, ranging from $50,000 to $100,000, making it difficult for smaller healthcare facilities to adopt these technologies .

Contamination Risks:

Blood culture contamination remains a significant issue, leading to false-positive results that complicate diagnosis and treatment decisions. Contaminated cultures can result in unnecessary treatments and increased healthcare costs.

Key Trends:

Technological Advancements:

Innovations in automated blood culture systems are improving the efficiency and accuracy of tests. The automated segment is anticipated to grow at the fastest pace, driven by advancements in testing technology.

Rising Incidence of Infections:

The prevalence of healthcare-associated infections continues to rise, with approximately 1 in 31 hospitalized patients in the U.S. suffering from such infections, driving the demand for blood culture tests.

Increased Healthcare Expenditure:

Rising global healthcare expenditure is facilitating the adoption of advanced diagnostic solutions, including blood culture tests. This trend supports the development and implementation of more efficient testing methods.

Focus on Sepsis Diagnostics:

There is a growing recognition of the importance of blood culture tests in diagnosing sepsis, which affects approximately 1.7 million individuals annually in the U.S., further propelling market demand.

What's inside a VMR industry report?

Our reports include actionable data and forward-looking analysis that help you craft pitches, create business plans, build presentations and write proposals.

Global Blood Culture Systems Market Regional Analysis

Here is a more detailed regional analysis of the global blood culture systems market:

North America:

North America accounted for 35% of the global blood culture tests market revenue in 2023, making it the largest market globally. This dominance is attributed to a well-established healthcare infrastructure and advanced diagnostic capabilities.

The region experiences a significant burden of bloodstream infections, with approximately 250,000 cases occurring annually in the U.S. alone. This high incidence drives demand for effective diagnostic tools like blood culture tests.

Technological Advancements: North America is at the forefront of technological innovations in blood culture testing, including automated systems that reduce turnaround times and improve accuracy. The presence of major players such as Becton, Dickinson and Company and bioMerieux enhances market growth through continuous product development.

Government-funded programs and initiatives aimed at improving infection control and management contribute to market growth. For example, funding from agencies like BARDA supports the development of advanced diagnostic technologies, which are crucial for timely infection diagnosis.

Asia Pacific

The Asia Pacific region is expected to exhibit the highest compound annual growth rate (CAGR) of 8.32% from 2023 to 2033, reflecting a significant demand for blood culture tests driven by increasing infection rates and healthcare advancements.

The region faces a growing incidence of bloodstream infections, including sepsis and hospital-associated infections. For instance, the World Health Organization estimates that around 49 million people suffer from sepsis globally each year, with a substantial number of cases occurring in Asia Pacific.

Countries like China and India are investing heavily in healthcare infrastructure and diagnostics, which enhances the capacity for early diagnosis and treatment of infectious diseases. This investment is crucial as the region aims to improve healthcare outcomes .

Increased awareness among healthcare professionals about the importance of accurate diagnosis of bloodstream infections is leading to greater acceptance and utilization of blood culture tests in clinical settings.

Global Blood Culture Systems Market: Segmentation Analysis

The Global Blood Culture Systems Market is Segmented on the Basis of Method, Product, Technology, Application, End-User And Geography.

Blood Culture Tests Market, By Method

  • Conventional/Manual Methods
  • Automated Methods

Based on Method, the market is segmented into Conventional/Manual Methods and Automated Methods. The conventional/manual methods dominate over automated methods. In 2023, conventional/manual blood culture methods held approximately 64.78% of the market share, making them the most widely used technique for blood culture testing. This dominance is attributed to their long-standing familiarity and acceptance among laboratory operators.

Blood Culture Tests Market, By Product

  • Consumables
  • Instruments
  • Software & Services

Based on Product, the market is segmented into Consumables, Instruments and Software & Services. The consumables segment accounted for the largest share of the blood culture tests market in 2023, with a revenue of approximately USD 3.5 Billion. This segment includes essential items such as blood culture media, reagents, assay kits, and other supplies necessary for conducting blood culture tests.

Blood Culture Tests Market, By Technology

  • Culture-based Technology
  • Molecular Technologies
  • Proteomics Technology

Based on Technology, the market is segmented into Culture-based Technology, Molecular Technologies and Proteomics Technology. The culture-based technology segment accounted for the largest share of the blood culture tests market in 2023, driven by its established effectiveness in detecting bacteria and fungi in blood samples. This segment remains the gold standard for diagnosing bloodstream infections.

Blood Culture Tests Market, By Application

  • Bacteremia
  • Fungemia
  • Mycobacterial Detection

Based on Application, the market is segmented into Bacteremia, Fungemia and Mycobacterial Detection. The bacteremia segment holds the largest share of the blood culture tests market, primarily due to the high prevalence of bacterial infections in bloodstream cases. Bacteremia is a critical condition that requires prompt diagnosis and treatment, making blood culture tests essential.

Blood Culture Tests Market, By End-User

  • Hospital Laboratories
  • Reference Laboratories
  • Academic Research Laboratories
  • Other

Based on End-User, the market is segmented into Hospital Laboratories, Reference Laboratories, Academic Research Laboratories and Other. Hospital laboratories accounted for more than 45% of the blood culture tests market share in 2023. This significant share is due to the high volume of tests conducted in hospitals, particularly for patients with infectious diseases.

Blood Culture Tests Market, By Geography

  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East and Africa
  • On the basis of Geography, the market is classified into North America, Europe, Asia Pacific, and the Rest of the World. Hospital laboratories accounted for more than 45% of the blood culture tests market share in 2023. This significant share is due to the high volume of tests conducted in hospitals, particularly for patients with infectious diseases.

Key Players

  • The "Global Blood Culture Tests Market" study report will provide valuable insight with an emphasis on the global market including some of the major players of the industry are
  • Thermo Fisher Scientific, Inc., T2 Biosystems, Inc., Cepheid, Inc., Roche Diagnostics, Beckman Coulter, BioMerieux SA, IRIDICA, Bruker Corporation, Nanosphere, Inc., Becton Dickinson and Company, Abbott Laboratories, Siemens Healthineers AG, Streck, Omega Diagnostics Group PLC, Qiagen N.V., BD Diagnostics, & F. Hoffmann-La Roche Ltd, among others.

Our market analysis offers detailed information on major players wherein our analysts provide insight into the financial statements of all the major players, product portfolio, product benchmarking, and SWOT analysis. The competitive landscape section also includes market share analysis, key development strategies, recent developments, and market ranking analysis of the above-mentioned players globally.

  • Blood Culture Tests Recent Developments
  • In February 2023, Cepheid announced the launch of its new Xpert(R) Blood Culture Identification (BCID) test, which provides rapid identification of pathogens directly from positive blood cultures. This test significantly reduces the time required to identify infectious agents, enhancing the speed of diagnosis and treatment.
  • In March 2023, Roche Diagnostics launched its new cobas(R) 8800 System for blood culture testing, which enhances the detection of pathogens in blood samples. This automated system is designed to provide faster results and improve workflow efficiency in clinical laboratories.

TABLE OF CONTENTS

1 INTRODUCTION OF GLOBAL BLOOD CULTURE TESTS MARKET

  • 1.1 Overview of the Market
  • 1.2 Scope of Report
  • 1.3 Assumptions

2 EXECUTIVE SUMMARY

3 RESEARCH METHODOLOGY OF VERIFIED MARKET RESEARCH

  • 3.1 Data Mining
  • 3.2 Validation
  • 3.3 Primary Interviews
  • 3.4 List of Data Sources

4 GLOBAL BLOOD CULTURE TESTS MARKET OUTLOOK

  • 4.1 Overview
  • 4.2 Market Dynamics
    • 4.2.1 Drivers
    • 4.2.2 Restraints
    • 4.2.3 Opportunities
  • 4.3 Porters Five Force Model
  • 4.4 Value Chain Analysis

5 GLOBAL BLOOD CULTURE TESTS MARKET, BY PRODUCT

  • 5.1 Overview
  • 5.2 Instruments
  • 5.3 Blood Culture Media
  • 5.4 Assay Kits & Reagents
  • 5.5 Blood Culture Accessories

6 GLOBAL BLOOD CULTURE TESTS MARKET, BY TECHNOLOGY

  • 6.1 Overview
  • 6.2 Polymerase Chain Reaction (PCR)
  • 6.3 Microarrays
  • 6.4 Culture-Based Technology
  • 6.5 Proteomics Technology

7 GLOBAL BLOOD CULTURE TESTS MARKET, BY APPLICATION

  • 7.1 Overview
  • 7.2 Bacteremia
  • 7.3 Fungemia
  • 7.4 Mycobacterial Detection

8 GLOBAL BLOOD CULTURE TESTS MARKET, BY GEOGRAPHY

  • 8.1 Overview
  • 8.2 North America
    • 8.2.1 U.S.
    • 8.2.2 Canada
    • 8.2.3 Mexico
  • 8.3 Europe
    • 8.3.1 Germany
    • 8.3.2 U.K.
    • 8.3.3 France
    • 8.3.4 Rest of Europe
  • 8.4 Asia Pacific
    • 8.4.1 China
    • 8.4.2 Japan
    • 8.4.3 India
    • 8.4.4 Rest of Asia Pacific
  • 8.5 Rest of the World
    • 8.5.1 Latin America
    • 8.5.2 Middle East And Africa

9 GLOBAL BLOOD CULTURE TESTS MARKET COMPETITIVE LANDSCAPE

  • 9.1 Overview
  • 9.2 Company Market Ranking
  • 9.3 Key Development Strategies

10 COMPANY PROFILES

  • 10.1 Biomerieux SA
    • 10.1.1 Overview
    • 10.1.2 Financial Performance
    • 10.1.3 Product Outlook
    • 10.1.4 Key Developments
  • 10.2 Nanosphere, Inc.
    • 10.2.1 Overview
    • 10.2.2 Financial Performance
    • 10.2.3 Product Outlook
    • 10.2.4 Key Developments
  • 10.3 Becton, Dickinson and Company
    • 10.3.1 Overview
    • 10.3.2 Financial Performance
    • 10.3.3 Product Outlook
    • 10.3.4 Key Developments
  • 10.4 Roche Diagnostics
    • 10.4.1 Overview
    • 10.4.2 Financial Performance
    • 10.4.3 Product Outlook
    • 10.4.4 Key Developments
  • 10.5 Thermo Fisher Scientific, Inc.
    • 10.5.1 Overview
    • 10.5.2 Financial Performance
    • 10.5.3 Product Outlook
    • 10.5.4 Key Developments
  • 10.6 Bruker Corporation
    • 10.6.1 Overview
    • 10.6.2 Financial Performance
    • 10.6.3 Product Outlook
    • 10.6.4 Key Developments
  • 10.7 Cepheid (Danaher Corporation)
    • 10.7.1 Overview
    • 10.7.2 Financial Performance
    • 10.7.3 Product Outlook
    • 10.7.4 Key Developments

11 Appendix

  • 11.1 Related Research
샘플 요청 목록
0 건의 상품을 선택 중
목록 보기
전체삭제